Monthly Archives: May 2015

zoom
-

Innovation Through An Academic Network: Part 3 The Future of Pharma

Looking ahead, our work is cut out for us in terms of R&D as many diseases and conditions are yet to be fully understood. By establishing partnerships with academia, we can further explore disease states, concentrate on early-stage molecule development, and optimize a product candidate. Not only is this relationship beneficial in terms of budgetary benefits (for both industry and academia), but it also increases engagement between pharma companies and the scientific community at large.

Continue reading

zoom
-

Innovation Through An Academic Network: Part 2 – Building New Channels to Advance Research

As we move into the Process Innovation era, new ways of developing more effective and safer treatments are required. In 2010, the number of drug approvals hit a record low, and several high profile molecules that had shown promise failed in the late stage of development. This was a huge loss for companies, who invested significant time, resources, and funds into the development of these molecules.

Continue reading

zoom
-

Innovation Through An Academic Network: Part 1 – The Evolution of the Pharmaceutical Landscape

Today, the pharma landscape is increasingly multifaceted, but it’s taken us a while to reach this moment in time. Fifteen years ago, the pharma landscape was centered on Product Performance: discovering or synthesizing molecules that deliver proven clinical results. Under this principle, sales reps marketed to and dealt directly with physicians, and there was little communication with or educational resources for consumers.

Continue reading

zoom
-

Cancer immunotherapy is providing options for patients who are out of options

Established in 2011 by Punit Dhillon, OncoSec Medical Inc. is a San Diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Through its proprietary technology, OncoSec aims to deliver safer and more effective cancer treatments that can provide long-term benefits for patients.

Continue reading